Christoph Fiehn1. 1. Unit for Rheumatology and Clinical Immunology, Medical Center Baden-Baden, Beethovenstr.2, 76530, Baden-Baden, Germany. c.fiehn@rheumatology-badenbaden.com.
Abstract
PURPOSE OF REVIEW: Familial chilblain lupus belongs to the group of type I interferonopathies and is characterized by typical skin manifestations and acral ischaemia. This review aims to give an overview of clinical signs and the pathophysiological mechanisms. RECENT FINDINGS: There are several mutations that can lead to this autosomal dominant disease. Most frequent is a mutation of the gene for TREX-1. However, as well cases of families with mutations in the SAMHD1 gene and, recently, with one for the gene that codes for the protein stimulator of interferon genes have been described. These genes are involved in the process of the detection of intracellular DNA, and their mutation results in an increased production of type I interferons and their gene products, resulting in auto-inflammation and auto-immunity. JAK inhibitors have been successfully used to treat this disorder. Familial chilblain is a rare disorder with very distinct clinical signs. Its pathophysiological mechanism gives insight into the process of interferon-induced inflammation in auto-immune diseases.
PURPOSE OF REVIEW: Familial chilblain lupus belongs to the group of type I interferonopathies and is characterized by typical skin manifestations and acral ischaemia. This review aims to give an overview of clinical signs and the pathophysiological mechanisms. RECENT FINDINGS: There are several mutations that can lead to this autosomal dominant disease. Most frequent is a mutation of the gene for TREX-1. However, as well cases of families with mutations in the SAMHD1 gene and, recently, with one for the gene that codes for the protein stimulator of interferon genes have been described. These genes are involved in the process of the detection of intracellular DNA, and their mutation results in an increased production of type I interferons and their gene products, resulting in auto-inflammation and auto-immunity. JAK inhibitors have been successfully used to treat this disorder. Familial chilblain is a rare disorder with very distinct clinical signs. Its pathophysiological mechanism gives insight into the process of interferon-induced inflammation in auto-immune diseases.
Entities:
Keywords:
Chilblain lupus; Interferon; JAK inhibitors; STING; hereditary
Authors: Jessica L Grieves; Jason M Fye; Scott Harvey; Jason M Grayson; Thomas Hollis; Fred W Perrino Journal: Proc Natl Acad Sci U S A Date: 2015-04-06 Impact factor: 11.205
Authors: Victoria Tüngler; Nadja König; Claudia Günther; Kerstin Engel; Christoph Fiehn; Martin Smitka; Maja von der Hagen; Reinhard Berner; Min Ae Lee-Kirsch Journal: Ann Rheum Dis Date: 2016-11-03 Impact factor: 19.103
Authors: Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens Journal: Proc Natl Acad Sci U S A Date: 2003-02-25 Impact factor: 11.205
Authors: Stefanie Kretschmer; Christine Wolf; Nadja König; Wolfgang Staroske; Jochen Guck; Martin Häusler; Hella Luksch; Laura A Nguyen; Baek Kim; Dimitra Alexopoulou; Andreas Dahl; Alexander Rapp; M Cristina Cardoso; Anna Shevchenko; Min Ae Lee-Kirsch Journal: Ann Rheum Dis Date: 2014-01-20 Impact factor: 19.103
Authors: Jorge Ocampo-Candiani; Cesar Jair Ramos-Cavazos; Maria Ivonne Arellano-Mendoza; Roberto Arenas-Guzmán; Angélica Beirana-Palencia; Alfredo Salmon-Demongin; Esperanza Welsh-Hernández; Horacio A Cabo; Minerva Gómez-Flores; Judith Dominguez-Cherit; Paulo Ricardo Criado; Helena Castro-López; Abraham Benjamin Alfaro-Sánchez; Alejandro García-Vargas; Emilia N Cohen-Sabban; Manuel Del Solar; Félix Fich; Gastón Galimberti; Carlos Fernando Gatti; José Luis López-Estebaranz; Omar Lupi; Miguel Olmos-Pérez; Ricardo Pérez-Alfonzo Journal: Int J Dermatol Date: 2021-05-08 Impact factor: 3.204
Authors: Esther E Freeman; Devon E McMahon; Jules B Lipoff; Misha Rosenbach; Carrie Kovarik; Seemal R Desai; Joanna Harp; Junko Takeshita; Lars E French; Henry W Lim; Bruce H Thiers; George J Hruza; Lindy P Fox Journal: J Am Acad Dermatol Date: 2020-07-02 Impact factor: 11.527
Authors: Colton J Garelli; Maggi Ahmed Refat; Padma P Nanaware; Zaida G Ramirez-Ortiz; Mehdi Rashighi; Jillian M Richmond Journal: Front Immunol Date: 2020-07-02 Impact factor: 7.561
Authors: Parnian Jamshidi; Bahareh Hajikhani; Mehdi Mirsaeidi; Hassan Vahidnezhad; Masoud Dadashi; Mohammad Javad Nasiri Journal: Front Med (Lausanne) Date: 2021-02-16
Authors: G Brancaccio; N Gussetti; L Sasset; M Alaibac; M Tarantello; R Salmaso; M Trevenzoli; A M Cattelan Journal: Pathog Glob Health Date: 2021-03-17 Impact factor: 2.894